SCHEMBL19341630

SCHEMBL19341630

O=C1COC2(CCN(C(c3ccccc3)c3ccccc3)C2)CN1

nearest known ligand 0.45

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ CYP2D6 P10635 10/20 0.45
▸ CYP3A4 P08684 10/20 0.45
▸ USP2 O75604 7/20 0.45
▸ CYP2C9 P11712 7/20 0.45
▸ ALDH1A1 P00352 2/20 0.45
▸ OPRM1 P35372 6/20 0.43
▸ OPRK1 P41145 6/20 0.43
▸ OPRL1 P41146 6/20 0.43
▸ OPRD1 P41143 5/20 0.43
▸ CYP1A2 P05177 6/20 0.42
▸ TSHR P16473 4/20 0.42
▸ CYP2C19 P33261 4/20 0.42
▸ TP53 P04637 1/20 0.41
▸ ALOX15 P16050 1/20 0.41
▸ RAB9A P51151 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1246058 0.89 NPSR1 (0.44) CYP2D6CYP3A4USP2CYP2C9ALDH1A1
SCHEMBL17611693 0.88 OPRM1 (0.43) CYP2D6CYP3A4USP2CYP2C9ALDH1A1
SCHEMBL17611773 0.88 OPRM1 (0.42) CYP2D6CYP3A4OPRM1OPRK1OPRL1
SCHEMBL19341594 0.76 USP2 (0.56) CYP2D6CYP3A4USP2CYP2C9ALDH1A1
SCHEMBL17609035 0.74 SIGMAR1 (0.56) CYP2D6CYP3A4OPRM1OPRK1OPRL1
SCHEMBL23856756 0.72 CYP2D6 (0.47) CYP2D6CYP3A4USP2CYP2C9ALDH1A1
SCHEMBL1977270 0.71 SIGMAR1 (0.58) CYP2D6CYP3A4CYP2C9ALDH1A1OPRM1
SCHEMBL21635325 0.70 SLC6A2 (0.32) CYP2D6TSHR
SCHEMBL11285193 0.69 LMNA (0.70) CYP2D6OPRM1TSHR
SCHEMBL21739433 0.68 TOP2A (0.33) ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170260185-A1 2-[BIS(4-FLUOROPHENYL)METHYL]-2,7-DIAZASPIRO[4.5]DECAN-10-ONE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF THE HUMAN DOPAMINE-ACTIVE-TRANSPORTER (DAT) PROTEIN FOR THE TREATMENT OF E.G. ATTENTION DEFICIT DISORDER (ADD) CHRONOS THERAPEUTICS LIMITED (GB) 2017-09-14 — — US disclosed
US-20170260185-A1 2-[BIS(4-FLUOROPHENYL)METHYL]-2,7-DIAZASPIRO[4.5]DECAN-10-ONE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF THE HUMAN DOPAMINE-ACTIVE-TRANSPORTER (DAT) PROTEIN FOR THE TREATMENT OF E.G. ATTENTION DEFICIT DISORDER (ADD) CHRONOS THERAPEUTICS LIMITED (GB) 2017-09-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170260185-A1 2-[BIS(4-FLUOROPHENYL)METHYL]-2,7-DIAZASPIRO[4.5]DECAN-10-ONE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF THE HUMAN DOPAMINE-ACTIVE-TRANSPORTER (DAT) PROTEIN FOR THE TREATMENT OF E.G. ATTENTION DEFICIT DISORDER (ADD) SLC6A3, SLC6A4, SLC6A2 CYP2D6 927/4885CYP3A4 518/4885USP2 2155/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback